Neurokinin receptor 3 peptide exacerbates 6-hydroxydopamine-induced dopaminergic degeneration in rats through JNK pathway

Journal of Neurochemistry

Volumn 123, Issue 3, 2012, Pages 417-427

  Chu, John Man Tak ^a   Chan, Ying Shing ^b   Chen, Liang Wei ^c   Yung, Ken Kin Lam ^a  

^a HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

6 OHDA; dopaminergic degeneration; dopaminergic neurons; JNK; neurokinin; neurokinin 3 receptor

Indexed keywords

APOMORPHINE; N [ALPHA (METHOXYCARBONYL)BENZYL] 2 PHENYL 4 QUINOLINECARBOXAMIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; NEUROKININ 3 RECEPTOR; OXIDOPAMINE; PROTEIN C JUN; SENKTIDE; SERINE; STRESS ACTIVATED PROTEIN KINASE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE EXACERBATION; DISEASE MODEL; DOPAMINERGIC NERVE CELL; ENZYME PHOSPHORYLATION; EXPERIMENTAL TEST; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SUBUNIT; RAT; ROTATION; ROTATION TEST; SUBSTANTIA NIGRA PARS COMPACTA; UPREGULATION; WESTERN BLOTTING;

ANIMALS; CORPUS STRIATUM; DOPAMINERGIC NEURONS; MALE; MAP KINASE SIGNALING SYSTEM; NERVE DEGENERATION; OXIDOPAMINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; RECEPTORS, NEUROKININ-3; SYMPATHOLYTICS;

RATTUS;

EID: 84867336094     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2012.07858.x     Document Type: Article

References (60)

1. Alonso R., Fournier M., Carayon P., Petitpretre G., Le Fur G., and, Soubrie P., (1996) Evidence for modulation of dopamine-neuronal function by tachykinin NK3 receptor stimulation in gerbil mesencephalic cell cultures. Eur. J. Neurosci. 8, 801-808. (Pubitemid 26114624)
2. Amadoro G., Pieri M., Ciotti M. T., Carunchio I., Canu N., Calissano P., Zona C., and, Severini C., (2007) Substance P provides neuroprotection in cerebellar granule cells through Akt and MAPK/Erk activation: Evidence for the involvement of the delayed rectifier potassium current. Neuropharmacology 52, 1366-1377. (Pubitemid 46601528)
3. Arundine M., and, Tymianski M., (2003) Molecular mechanisms of calcium-dependent neurodegeneration in excitotoxicity. Cell Calcium 34, 325-337. (Pubitemid 37021228)
4. Bannon M. J., Brownschidle L. A., Tian Y., Whitty C. J., Poosch M. S., D'sa C., and, Moody C. A., (1995) Neurokinin-3 receptors modulate dopamine cell function and alter the effects of 6-hydroxdopamine. Brain Res. 695, 19-24.
5. Barker R., (1996) Tachykinins, neurotrophism and neurodegenerative disease; a critical review on the possible role of tachykinins in the etiology of CNS diseases. Rev. Neurosci. 7, 187-214. (Pubitemid 26397659)
6. Beal M. F., (1992) Mechanism of excitatory in neurological disease. FASEB J. 6, 3338-3344.
7. Beal M. F., (2001) Experimental models of Parkinson's disease. Nat. Rev. Neurosci. 2, 325-334.
8. Berger K., Przedborski S., and, Cadet J. L., (1991) Retrograde degeneration of nigrostriatal neurons induced by intrastriatal 6-hydroxydopamine injection in rats. Brain Res. Bull. 26, 301-307.
9. Blandini F., Porter R. H., and, Greenamyre J. T., (1996) Glutamate and Parkinson's disease. Mol. Neurobiol. 12, 73-94. (Pubitemid 126718053)
10. Blandini F., Mappi G., Tassorelli C., and, Martignoni E., (2000) Functional changes of the basal ganglia circuitry in Parkinson's disease. Prog. Neurobiol. 62, 63-88. (Pubitemid 30252017)
11. Borsello T., and, Forloni G., (2007) JNK signaling: a possible target to prevent neurodegeneration. Curr. Pharm. Des. 13, 1875-1886. (Pubitemid 47010160)
12. Bove J., Prou D., Perier C., and, Przedborski S., (2005) Toxin-induced models of Parkinson's disease. NeuroRx 2, 484-494. (Pubitemid 41444882)
13. Brecht S., Kirchhof R., Chromik A., et al. (2005) Specific pathophysiological functions of JNK isoforms in the brain. Eur. J. Neurosci. 21, 363-377. (Pubitemid 40204240)
14. Cadet J. L., Katz M., Jackson-Lewis V., and, Fahn S., (1989) Vitamin E attenuates the toxic effects of intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats: behavioral and biochemical evidence. Brain Res. 476, 10-15. (Pubitemid 19006358)
15. Calvo N., Reiriz J., Perez-Navarro E., and, Alberch J., (1996) Tachykinins protect cholinergic neurons from quinolinic acid excitotoxicity in striatal cultures. Brain Res. 740, 323-328. (Pubitemid 26411315)
16. Centeno C., Repici M., Chatton J., et al. (2007) Role of the JNK pathway in NMDA-mediated excitotoxicity of cortical neurons. Cell Death and Diff. 14, 240-253. (Pubitemid 46092227)
17. Chen L. W., Guan Z. I., and, Ding Y. Q., (1998) Mesencephalic dopaminergic neurons expressing neuromedin K receptor (NK3): a double immunocytochemical study in the rat. Brain Res. 780, 150-154.
18. Chen L. W., Yung K. K. L., and, Chan Y. S., (2004) Neurokinin peptides and neurokinin receptors as potential therapeutic intervention targets of basal ganglia in the prevention and treatment of Parkinson's disease. Curr. Drug Target 5, 197-206. (Pubitemid 38292005)
19. Chen L. W., Wang Y. Q., Bian G. L., Wei L. C., and, Yung K. L., (2008) Neurokinin 3 peptide instead of neurokinin 1 synergistically exacerbates kainic acid-inducing degeneration of neurons in the substantia nigra of mice. J. Neurochem., 105, 203-216.
20. Chu J. M. T., Chan Y. S., Chen L. W., and, Yung K. L., (2011) Neuroprotective effects of neurokinin receptor one in dopaminergic neurons are mediated through Akt/PKB cell signaling pathway. Neuropharamacology 61, 1-10.
21. Dam Y. Q., Escher E., and, Quirion R., (1990) Visualization of neurokinin-3 receptor sites in rat brain using the highly selective ligand [3H] senktide. Brain Res. 506, 175-179. (Pubitemid 20020094)
22. Davis R. J., (1994) MAPKs: new JNK expands the group. Trends Biochem. Sci. 19, 470-473. (Pubitemid 24342759)
23. Ding Y. Q., Shigemoto R., Takada M., Ohishi H., Nakanishi S., and, Mizuno N., (1996) Localization of the neuromedin K receptor (NK3) in the central nervous system of the rat. J. Comp. Neurol. 364, 290-310. (Pubitemid 26035154)
24. Doble A., (1999) The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmcol. Ther. 81, 163-221. (Pubitemid 29094735)
25. Enslen H., Tokumitsu H., Stork P. J., Davis R. J., and, Soderling T. R., (1996) Regulation of mitogen-activated protein kinases by a calcium/calmodulin- dependent protein kinase cascade. PNAS 93, 10803-10808.
26. Ichijo H., (1999) From receptors to stress-activated MAP kinases. Oncogene 18, 6087-6093.
27. Johnson G. L., and, Nakamura K., (2007) The c-Jun kinase/stress-activated pathway: regulation, function and role in human disease. BBA-Mol. Cell Res. 1773, 1341-1348. (Pubitemid 47125977)
28. Karcz-Kubicha M., Lorenz B., and, Danysz W., (1999) GlycineB antagonists and partial agonists in rodent models of Parkinson's disease-comparison with uncompetitive N-methyl-D-aspartate receptor antagonist. Neuropharmacology 38, 109-119. (Pubitemid 29073530)
29. Karin M., Liu Z. G., and, Zandi E., (1997) AP-1 function and regulation. Curr. Opin. Cell Bio. 9, 240-246. (Pubitemid 27135992)
30. Keegan K. D., Woodruff G. N., and, Pinnock R. D., (1992) The selective NK3 receptor agonist senktide excites a subpopulation of dopamine-sensitive neurons in the rat substantia nigra pars compacta in vitro. Br. J. Pharmacol. 105, 3-5.
31. Khawaja A. M., and, Rogers D. F., (1996) Tachykinins: receptor to effector. Int. J. Biochem. Cell Biol. 28, 721-738. (Pubitemid 26181860)
32. Kim J., and, Sharma R. P., (2004) Calcium-mediated activation of c-Jun NH2-Terminal Kinase (JNK) and apoptosis in response to cadmium in murine macrophages. Toxicol. Sci. 81, 518-527. (Pubitemid 39377981)
33. Kirik D., Rosenblad C., and, Bjorklund A., (1998) Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp. Neurol. 152, 259-277. (Pubitemid 28419264)
34. Kyriakis J. M., and, Avruch J., (2001) Mammalian Mitogen-Activated Protein Kinase signal transduction pathways activated by stress and inflammation. Physiol. Rev. 81, 807-869. (Pubitemid 32267078)
35. 2+-MAPK/ERK pathways. J. Neurochem., 87, 508-521. (Pubitemid 37255258)
36. Langlois X., Wintmolders C., Riele P. T., Leysen J. E., and, Jurzak M., (2001) Detailed distribution of neurokinin 3 receptors in the rat, guinea pig and gerbil brain: a comparative autoradiographic study. Neuropharmacology 40, 242-253.
37. Leppa S., and, Bohmann D., (1999) Diverse functions of JNK signaling and c-Jun in stress response and apoptosis. Oncogene 18, 6158-6162.
38. Loftis J. M., and, Janowsky A., (2003) The N-methyl-D-aspartic receptor subunit NR2B: localization, functional properties, regulation, and clinical implications. Pharmacol. Ther. 97, 55-85. (Pubitemid 35477804)
39. Maggi C. A., (2000) Principles of tachykininergic co-transmission in the peripheral and enteric nervous system. Regul Pept 93, 53-64.
40. Maggi C. A., Patacchini R., Rovero P., and, Giachetti A., (1993) Tachykinin receptors and tachykinin receptor antagonists. Auton. Autacoid Pharmacol. 13, 23-93. (Pubitemid 23054476)
41. Marco N., Thirion A., Mons G., Bougault I., Fur G. L., Soubrie P., and, Steinberg R., (1998) Activation of dopaminergic and cholinergic neurotransmission by tachykinin NK3 receptor stimulation an in vivo microdialysis approach in guinea pig. Neuropeptides 32, 481-488. (Pubitemid 28509015)
42. Mattson M. P., (2007) Calcium and neurodegeneration. Aging Cell 6, 337-350.
43. Nakanishi S., (1991) Mammalian tachykinin receptors. Ann. Rev. Neurosci. 14, 123-136.
44. Nakanishi S., (1992) Molecular diversity of glutamate receptors and implications of brain function. Science 258, 597-603.
45. Nordquist R. E., Durkin S., Jacquet A., and, Spooren W., (2008) The tachykinin NK3 receptor agonist senktide induces locomotor activity in male Mongolian gerbils. Eur. J. Pharmacol. 600, 87-92.
46. Olofsson M. H., Havelka A. M., Brnjic S., Shoshan M., and, Linder S., (2008) Charting calcium-regulated apoptosis pathways using chemical biology: role of calmodulin kinase II. BMC Chem. Biol. 8, 2.
47. Otsuka M., and, Yoshioka K., (1993) Neurotransmitter functions of mammalian tachykinins. Physiol. Rev., 73, 229-308. (Pubitemid 23119035)
48. Paxinos P., and, Watson C., (1986) The Rat Brain in Stereotaxic Coordinates. San Diego, Academic Press.
49. Peng J., and, Andersen J. K., (2003) The role of c-Jun N-terminal kinase (JNK) in Parkinson's disease. IUBMB Life 55, 267-271. (Pubitemid 36842258)
50. Przedborski S., Leviver M., Jiang H., Ferreira M., Jackson-Lewis V., Donaldson D., and, Togasaki D. M., (1995) Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience 67, 631-647.
51. Salthun-Lassalle B., Traver S., Hirsch E. C., and, Michel P. P., (2005) Substance P, neurokinin A and B, and synthetic tachykinin peptides protect mesencephalic dopaminergic neurons in culture via an activity-dependent mechanism. Mol. Pharmaco. 68, 1214-1224. (Pubitemid 41539979)
52. Sauer H., Rosenblad C., and, Bjorklund A., (1995) Glial cell line-derived neurotrophic factor but not transforming growth factor 03 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion. PNAS 92, 8935-8939.
53. Severini C., Improta G., Falconieri-Erspamer G., Salvadori S., and, Erspamer V., (2002) The tachykinin peptide family. Pharmacol. Rev., 54, 285-332.
54. Severini C., Ciotti M. T., Mercanti D., Barbato C., and, Calissano P., (2003) A tachykinin-like factor increases glutamate toxicity in rat cerebellar granule cells. Neuropharmacology 44, 117-124. (Pubitemid 36135849)
55. Shaulian E., and, Karin M., (2002) AP-1 as a regulator of cell life and death. Nat. Cell Biol. 4, 131-136.
56. Shen H. M., and, Liu Z. G., (2006) JNK signaling pathway is a key modulator in cell death mediated by reactive oxygen and nitrogen species. Free Radic. Biol. Med. 40, 928-939.
57. Tenovuo O., Kolhinen O., Laihinen A., and, Rinne U. K., (1990) Brain substance P receptors in Parkinson's disease. Adv. Neurol., 53, 145-148.
58. Wang Y. Q., Hu H. J., Cao R., and, Chen L. W., (2005) Differential co-localization of neurokinin-3 receptor and NMDA/AMPA receptor subunits in neurons of substantia nigra of C57/BL mice. Brain Res. 1053, 207-212. (Pubitemid 41116807)
59. Yang D. D., Kuan C. Y., Whitmarsh A. J., Rinocn M., Zheng T. S., Davis R. J., Rakic P., and, Flavell R. A., (1997) Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene. Nature 389, 865-870. (Pubitemid 27462982)
60. Zhang X. Q., Andren P. E., Chergui K., and, Svenningsson P., (2008) Neurokinin B/NK3 receptors exert feedback inhibition on L-DOPA actions in the 6-OHDA lesion rat model of Parkinson's disease. Neuropharmacology 54, 1143-1152.